Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak (michal.masternak@ucf.edu) for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 14, Number 4, 2009

The new two-component conformity index formula (TCCI) and dose-volume comparisons of the pituitary gland and tonsil cancer IMRT plans using a linear accelerator and helical Tomotherapy

Tomasz Piotrowski,  Piotr Martenka, Nathalie de Patoul, Agata Jodda, Maxime Coevoet, Julian Malicki, Stefaan Vynckier

Summary:

Background/Aim

To examine the new dose-volume verification tool, called the two-component conformity index formula (TCCI), for tumours of the pituitary gland and tonsil cancer IMRT plans using helical Tomotherapy and a linear accelerator.

Material and Methods

10 medically inoperable patients – 5 with tumour of the pituitary gland and 5 tonsil cancers – were considered. Tomotherapy and Eclipse plans were compared by DVH analysis and new TCCI analysis including: 1/ the physician's intents for dose distribution in PRVs, 2/ more than one dose-volume constraint for dose distribution in PTV and healthy tissues, and 3/ separation between coverage and excess components.

Results

DVH analysis shows differences for the PTV received doses close to the prescription dose (PD): 1/in pituitary gland, Eclipse – 61% of PTV volume enclosed by PD and Tomotherapy – 50%, and 2/in tonsil cancer, Eclipse plans – 44% and Tomotherapy – 55%. These differences were clinically confirmed for tonsil cancer through TCCI analysis. Moreover, TCCI analysis shows better coverage of PTV volume through 90% and 95% isodose levels for Tomotherapy plans. Better high dose region reduction for brain stem and optic chiasm in pituitary gland and middle dose region reduction for parotids and spinal cord in tonsil and dose reduction in healthy tissues reported by TCCI analysis were observed for Tomotherapy plans.

Conclusions

The usefulness of the information provided means that TCCI could be used as a primary or alternative method of quick dose-volume verification finally supported by advanced DVH analysis.

Signature: Rep Pract Oncol Radiother, 2009; 14(4) : 133-145


« back

 
INDEXED IN:

Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.

http://www.sciencedirect.com/science/journal/15071367/19/2